**Core tip:** Pregnancy is a prothrombotic state and can cause adverse outcome in patients with Budd-Chiari syndrome (BCS). In our study, maternal outcome in patients with known and treated BCS was good. However, most deliveries were carried out by emergency caesarean section (7/10). There was high incidence of placental disease leading to caesarean section. Fetal outcome beyond 20 wk gestation was also good. With careful monitoring of anti-coagulation, there were no cases of thrombosis and only a minority of patients had noteworthy bleeding complications. Development of pulmonary hypertension in two patients several years after TIPSS is an important finding that warrants further studies.

INTRODUCTION
============

Budd-Chiari syndrome (BCS) is a rare disorder caused by hepatic venous outflow obstruction and resulting hepatic dysfunction due to sinusoidal congestion, ischaemic injury to the liver and portal hypertension. The main mechanism for BCS is thrombosis of the hepatic veins or of the terminal portion of the inferior vena cava\[[@B1],[@B2]\]. The management using a stepwise regimen is largely successful with anticoagulation and interventional radiology alone. Stepwise regimen includes; (1) anticoagulant therapy for an indefinite period of time; (2) angioplasty or stenting for stenosis of hepatic veins; and (3) decompressive techniques \[surgical shunt or transjugular intrahepatic porto-systemic shunts (TIPSS)\], for patients who are non-responsive to medical treatment or not candidates for angioplasty/stenting\[[@B3]\]. TIPSS has a lower morbidity and mortality rate than surgery and is a preferred approach. The outcomes are favourable with 10-year survival approaching 90%\[[@B4],[@B5]\].

Usually multiple risk factors for venous thromboembolism are present in patients with BCS\[[@B1],[@B6]-[@B8]\]. In one study, 84% of 163 patients with BCS had at least one thrombotic risk factor, and 46% of these patients had more than one prothrombotic risk factor; the most common was myeloproliferative neoplasia (MPN) (49% of 103 tested patients)\[[@B9]\]. In another study of 43 women with BCS, at least one thrombotic risk factor (not considering pregnancy as risk factor) was identified in 40 women (93%) including MPN in 56% of study participants\[[@B10]\]. Other thrombotic risk factors include mutation in Factor V Leiden and prothrombin gene, protein C, protein S or antithrombin deficiency, antiphospholipid syndrome, hyperhomocysteinemia and paroxysmal nocturnal haemoglobinuria. BCS may also be a complication of systemic vasculitides such as Bechet's disease\[[@B11]\].

BCS mainly affects women of childbearing age and pregnancy can be a crucial issue. There is conflicting data on prevalence of pregnancy related BCS. A systematic review and meta-analysis of twenty studies demonstrated a pooled prevalence of pregnancy-related BCS of 6.8%\[[@B12]\]. However another study showed that pregnancy is unlikely to cause BCS in the absence of other thrombotic risk factors\[[@B10]\].

Pregnancy is a hypercoagulable state and earlier studies reported that women with BCS could be at risk of developing severe exacerbation of their underlying disease during pregnancy\[[@B13],[@B14]\]. Rautou et al\[[@B15]\] conducted a study on outcome of pregnancy in women with known and treated BCS and concluded that good maternal outcome could be achieved with current treatment modalities and close surveillance of BCS. Therefore, BCS cannot be considered a contraindication to pregnancy in stable patients with well-controlled disease.

As the available literature on pregnancy complications in women with known BCS remains scarce, we performed this study of women treated at our tertiary centre for BCS who had become pregnant.

MATERIALS AND METHODS
=====================

We used the definitions related to outcome of pregnancies as previously described by Rautou et al\[[@B15]\]: (1) date of diagnosis of BCS: the first imaging modality showing an obstructed venous outflow tract; and (2) miscarriages: A spontaneous loss of pregnancy before 20 weeks' of gestation. Outcome of the pregnancy: (1) favourable: Live birth occurred at 32 or more completed weeks of gestation, with a healthy infant and no serious obstetrical complication (bar intrahepatic cholestasis); and (2) poor: Otherwise pregnancy outcome. Rotterdam prognostic index was calculated as previously described\[[@B16]\].

The electronic records of all female patients diagnosed with BCS between January 2001 and December 2015 at our tertiary care referral center were retrospectively analysed. The data was collected prospectively and radiology records of these patients were also searched. Those that became pregnant during the follow-up for BCS were included in the study. Patients in whom pregnancy occurred before BCS was diagnosed were excluded.

All patients were tested for the known prothrombotic factors. Combined oral contraceptive pill (OCP) use within the 3 mo preceding diagnosis of BCS was considered a thrombotic risk factor.

Where possible, patients had pre-pregnancy counselling and were made aware of the potential complications that may occur during pregnancy. Patients with known varices or portal hypertension had pre-pregnancy gastroscopy to ensure varices had been treated. These patients had further gastroscopies for variceal surveillance during second trimester. Patients with TIPSS had regular abdominal ultrasound to ensure patency of the TIPSS. The patients were monitored in a joint haematological/obstetric clinic.

Given the risk of embryopathy and fetal loss associated with warfarin, low molecular weight heparin (LMWH) was substituted for warfarin as soon as pregnancy was diagnosed, or prior to conception in one patient who had two *in-vitro* fertilisation treatments. The dose of LMWH was adjusted to maintain therapeutic factor Xa activity in selected cases under haematology supervision. LMWH treatment was replaced by warfarin following the delivery.

RESULTS
=======

Baseline characteristics
------------------------

Fifty-three female patients under follow-up for BCS were identified. Out of these, 7 patients had 16 pregnancies during the study period.

Median age of diagnosis of BCS was 25 years (range 21-34 years). Five (71%) patients had abdominal pain as the presenting complaint and symptoms were mainly chronic in nature. One patient had variceal haemorrhage and three patients had ascites on presentation of BCS. None of them had hepatic encephalopathy. None of the patients had other significant co-morbidities when the diagnosis of BCS was established. The characteristics of these patients including Rotterdam and Clichy scores at the time of diagnosis of BCS are given in Table [1](#T1){ref-type="table"}. The laboratory values were stable at time of conception in all patients and ascites had resolved.

###### 

Baseline characteristics of the patients at presentation

  **Patient ID**                                   **1**                                                **2**                                                    **3**                                                                                **4**                                            **5**                                                                                          **6**                                                                                                                               **7**
  ------------------------------------------------ ---------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------------------------------------ ------------------------------------------------ ---------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- -----------------------
  Age at diagnosis (yr)                            34                                                   21                                                       30                                                                                   21                                               31                                                                                             24                                                                                                                                  25
  Symptoms at presentation                         Ascites                                              Oesophageal variceal haemorrhage, abdominal pain         Abdominal pain; ascites                                                              Abdominal pain, ascites                          Abdominal pain, fever, mouth ulcers                                                            Ascites, renal failure and sepsis (ITU admission)                                                                                   Abdominal pain
  Risk factors for BCS                             JAK 2 positive MPD; OCP                              JAK 2 positive mutation                                  None identified                                                                      Factor V Leiden; OCP                             JAK2 positive MPD (Essential Thrombocythaemia); Factor V Leiden                                JAK 2 positive mutation                                                                                                             Factor V Leiden
  Encephalopathy                                   None                                                 None                                                     None                                                                                 None                                             None                                                                                           None                                                                                                                                None
  Ascites                                          Moderate                                             Mild                                                     Mild                                                                                 Mild                                             None initially                                                                                 Severe                                                                                                                              Moderate
  INR                                              1.7                                                  1.4                                                      1.2                                                                                  1.3                                              1.7                                                                                            1.4                                                                                                                                 1.5
  Albumin (g/L)                                    28                                                   37                                                       49                                                                                   49                                               49                                                                                             25                                                                                                                                  26
  Bilirubin (umol/L)                               19                                                   18                                                       20                                                                                   18                                               11                                                                                             51                                                                                                                                  32
  ALT (U/L)                                        \-                                                   31                                                       \-                                                                                   57                                               \-                                                                                             \-                                                                                                                                  \-
  AST (U/L)                                        134                                                  49                                                       20                                                                                   34                                               27                                                                                             277                                                                                                                                 43
  Urea (mmol/L)                                    2.7                                                  2.3                                                      2.9                                                                                  4.7                                              2.9                                                                                            4.4                                                                                                                                 2
  Creatinine (mmol/L)                              72                                                   43                                                       70                                                                                   68                                               51                                                                                             92                                                                                                                                  70
  Sodium (mmol/L)                                  143                                                  137                                                      143                                                                                  142                                              140                                                                                            130                                                                                                                                 133
  MELD                                             19                                                   14                                                       6                                                                                    10                                               12.37                                                                                          14                                                                                                                                  17
  UKELD                                            53                                                   53                                                       48                                                                                   49                                               49                                                                                             49                                                                                                                                  55
  Hb (g/L)                                         137                                                  121                                                      155                                                                                  128                                              150                                                                                            147                                                                                                                                 88
  WCC (10^9^/L)                                    7.9                                                  9.6                                                      10.9                                                                                 5.7                                              5.7                                                                                            28.8                                                                                                                                6.8
  Platelets (10^9^/L)                              345                                                  183                                                      307                                                                                  247                                              411                                                                                            400                                                                                                                                 226
  Rotterdam PI                                     1.116                                                0.072                                                    1.12                                                                                 0.07                                             1.08                                                                                           1.244                                                                                                                               1.168
  Clichy PI                                        4.39                                                 1.99                                                     3.13                                                                                 4.04                                             3.44                                                                                           7.54                                                                                                                                7.55
  Liver biopsy                                     Not done                                             Not done                                                 Not done                                                                             Suggestive of hepatic vein obstruction           Consistent with Hepatic venous outflow obstruction                                             Not done                                                                                                                            Not done
  Level of obstruction                             Left hepatic vein                                    Hepatic vein                                             Hepatic vein                                                                         Hepatic Vein                                     Right Hepatic Vein                                                                             Left Hepatic vein                                                                                                                   Hepatic vein
  Radiological intervention                        TIPSS                                                TIPSS                                                    None                                                                                 Angioplasty and Stenting to Hepatic vein         Right Hepatic Vein dilatation                                                                  TIPSS                                                                                                                               TIPSS
  Type of TIPSS                                    Viatorr (covered)                                    Viatorr (covered)                                        \-                                                                                   \-                                               \-                                                                                             Memotherm, then Viatorr                                                                                                             Memotherm (Uncovered)
  Medications post intervention                    Warfarin                                             Warfarin                                                 N/A                                                                                  Warfarin                                         Warfarin                                                                                       Warfarin, Interferon                                                                                                                Warfarin
  Duration of follow up (yr)                       4                                                    5                                                        7                                                                                    3                                                13                                                                                             14                                                                                                                                  14
  Comments/ complications following intervention   TIPSS Stent redilatation after a week of insertion   TIPSS stent stenosis - needed to be re-dilated in 2 yr   Maintained on oral anticoagulation (warfarin) and did not require any intervention   Vascular Wallstent was re-canalized after 2 yr   Inferior RHV dilated 5 yr after the diagnosis (developed ascites and had compliance issues).   Bleeding from hepatic nodule (with INR \> 9). Managed conservatively. Later stent was changed to a covered one for TIPSS stenosis   \-

MPD: Myeloproliferative disorder; TIPSS: Trans-jugular intrahepatic posto-systemic shunt; OCP: Oral contraceptive pills; INR: International normalised ratio; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; MELD: Model for end-stage liver disease; UKELD: United Kingdom model for end-stage liver disease; Hb: Haemoglobin; WCC: White cell count.

BCS was managed by anticoagulation therapy and radiological interventions with the aim to recanalise any outflow obstruction. Six out of the 7 patients underwent liver decompression procedures before conception. Procedures included dilatation of right hepatic vein (one patient), TIPSS (in four patients) and right hepatic vein stenting (one patient). One patient did not have any intervention for decompression and was managed with oral anticoagulation (warfarin) alone. All patients had anticoagulation. None of the patients in our series required surgical porto-systemic shunting or liver transplantation as a definite treatment of BCS.

At least one causal factor for hepatic vein obstruction was identified in 6 of these 7 women (86%). JAK 2V617F mutation alone was seen in 2 patients; factor V Leiden alone in one; JAK 2 mutation and factor V Leiden in one patient; JAK 2 mutation and OCP use in one patient; and factor V Leiden and OCP use in one patient. One patient did not have any identifiable risk factor.

Pregnancy course
----------------

Median age at conception was 32 years (range 23-39). Median time between diagnosis of BCS and conception was 5 years (range 3 mo-13 years). Follow up after the diagnosis of BCS in the seven women with pregnancies was for a median of 7 years (range 3-14 years). All patients that became pregnant had well compensated liver disease at the time of each conception and stigmata of decompensation of liver disease (ascites, in majority of patients at presentation) were no longer present at the time of any pregnancy. Gestational course is detailed in Table [2](#T2){ref-type="table"}.

###### 

Gestational course and perinatal complications in 16 pregnancies

  **Patient No**.   **Pregnancy No**.   **Age at gestation (yr)**   **Anticoagulation during pregnancy**                                                              **Mode of delivery**          **Weeks gestation**   **Birth weight**   **Foetal/infant condition**                                             **Maternal condition**
  ----------------- ------------------- --------------------------- ------------------------------------------------------------------------------------------------- ----------------------------- --------------------- ------------------ ----------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1                 1                   37                          LMWH                                                                                              Vaginal                       36                    2645 g             Neonatal jaundice, treatment with antibiotics for suspected infection   
  2                 2                   24                          LMWH                                                                                              Emergency caesarean section   35                    2140 g             Fetal distress (reduced foetal movements)- Healthy baby                 ICP OGDs during pregnancy, no varices seen
  3                 3                   35                          LMWH                                                                                              Vaginal delivery              35                    2600 g             Mild Jaundice                                                           *In-vitro* fertilization treatment
  3                 4                   37                          LMWH                                                                                              Vaginal delivery              37                    2450 g             Healthy                                                                 *In-vitro* fertilization treatment Primary post-partum haemorrhage secondary to retained placenta that was surgically evacuated
  4                 5                   23                          LMWH                                                                                              Caesarean section             37                    2645 g             Fetal distress - Healthy baby post delivery                             ...
  5                 6                   36                          LMWH and Aspirin (switched from warfarin and Hydroxyurea at 22 wk when pregnancy was diagnosed)   Emergency caesarean section   37                    3115 g             Breech presentation                                                     Had several gastroscopies (OGD) and banding to Oesophageal Varices during pregnancy
  5                 7                   39                          Warfarin                                                                                          Miscarriage                   5                     \-                 \-                                                                      PV bleeding; was not aware of conception
  6                 8                   31                          LMWH                                                                                              Emergency Caesarean Section   27                    Not available      Healthy boy                                                             Bleeding secondary to placental abruption ICP from 25 wk
  6                 9                   37                          LMWH, Aspirin, interferon for MPD (Myeloproliferative disorder)                                   Emergency Caesarean section   35                    Not available      Fetal distress. Healthy baby                                            ICP Minor subchorionic bleeding at 12 and 23 wk. LMWH reduced, aspirin stopped temporarily. Changes resolved on subsequent scans. Presentation with PH and suspected placental abruption at 35 wk Secondary post-partum haemorrhage treated with surgical of uterine clot evacuation and Rusch Balloon
  7                 10                  25                          LMWH                                                                                              Miscarriage                   9                     \-                 \-                                                                      \-
  7                 11                  27                          LMWH                                                                                              Miscarriage                   20                    \-                 Congenital pneumonia and mild amnionitis                                Weakness of cervix;
  7                 12                  28                          LMWH                                                                                              Miscarriage                   19                    \-                 \-                                                                      Placental abruption Weakness of cervix; Placental abruption
  7                 13                  29                          LMWH                                                                                              Emergency Caesarean Section   35                    2974 g             Healthy boy                                                             Dyspnoeic during 3^rd^ Trimester; ICP in 20 wk onwards; C-Section for difficult labour (cervical suture could not be removed)
  7                 14                  31                          LMWH                                                                                              Failed Pregnancy              10                    \-                 \-                                                                      Surgical removal of retained products of Contraception
  7                 15                  33                          LMWH                                                                                              Miscarriage                   7                     \-                 \-                                                                      \-
  7                 16                  34                          LMWH                                                                                              Emergency Caesarean Section   35                    2440 g             Healthy boy                                                             Pre-eclampsia; Breathlessness during 3^rd^ trimester, PH diagnosed after pregnancy

LMWH: Low molecular weight heparin; ICP: Intrahepatic cholestasis of pregnancy; PH: Pulmonary hypertension.

Aspirin (along with LMWH) was administered to one patient in 2 pregnancies (patient 6) for Essential Thrombocytosis. This patient was also treated with interferon for JAK 2 positive MPN. No patient was treated with beta-blockers during pregnancy.

Six out of the 16 (38%) pregnancies miscarried with fetal loss before 20 wk gestation. Six miscarriages/failed pregnancies occurred in 2 patients. One miscarried at 5 wk when she presented with vaginal bleeding. She was not aware of the pregnancy. The other patient had 5 miscarriages over a 9-year period. Two out of 5 were after the first trimester and these were attributed to cervical weakness and, therefore, she had cervical sutures in the following pregnancies (after 13 wk of gestation) leading to two successful deliveries.

Out of the 10 pregnancies reaching beyond 20 wk gestation, there were 3 vaginal deliveries and 7 caesarean sections. There was one very preterm birth at 27 wk and 5 preterm deliveries between 32 and 35 wk gestation, all with favourable neonatal outcomes. Four pregnancies resulted in delivery after 36-wk gestation, again all with favourable outcome.

Seven (70%) infants were delivered *via* emergency caesarean sections. Indications for caesarean section were varied, including fetal distress in three pregnancies; pre-eclampsia in one, breech presentation in one, bleeding from placenta praevia in one patient and difficult labour due to cervical suture in one patient.

Specific complications
----------------------

Four patients developed intrahepatic cholestasis of pregnancy (ICP) in five pregnancies and they were treated with ursodeoxycholic acid. One patient had pre-eclampsia needing emergency caesarean section.

Significant PV bleeding occurred after 3 pregnancies in 2 patients (patients 3 and 6 in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). One patient (patient 3) had a primary post-partum haemorrhage secondary to a retained placenta that was surgically removed. The other patient (patient 6) had a complicated first pregnancy with placental abruption at 27 wk gestation and needed emergency caesarean section. In her second pregnancy, she had secondary postpartum haemorrhage following caesarean section for suspected placental abruption. It was treated with surgical evacuation of uterine clot and insertion of a Rusch Balloon. There were no cases of variceal haemorrhage.

One patient, (patient 5) underwent regular gastroscopies for banding of (non-bleeding) oesophageal varices. That patient was not treated with beta-blockers during pregnancy. There were no cases of thrombosis in any of the pregnancies.

Two patients (patients 6 and 7) developed symptoms of pulmonary hypertension (PH) during the course of pregnancy and are described as follows.

Case 1
------

This patient had second pregnancy at the age of 37 years (13 years after the diagnosis and treatment of BCS). She had minor subchorionic bleeding noted on ultrasound during pregnancy. At 35 wk of gestation, this patient had emergency caesarean section for suspected placental abruption and developed respiratory failure post operatively. Trans-thoracic echocardiography (TTE) suggested PH with pulmonary artery systolic pressure estimated at 60-65 mmHg. CT scan excluded pulmonary embolism and showed patent TIPSS and mild splenomegaly. Right heart catheterisation confirmed the presence of PH with mean pulmonary artery pressure (mPAP) of 37 mmHg and pulmonary artery wedge (PAWP) pressure of 12 mmHg. She is being treated with Sildenafil (phosphodiesterase inhibitor) and Macitentan (endothelin receptor antagonist) for PH. Follow up investigations demonstrated improved exercise tolerance with no significant limitations in activities of daily living (patient 6; Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}).

Case 2
------

This patient delivered her second child at 34 years of age, 9 years after the diagnosis and treatment of BCS. Caesarean section was performed at 35-wk gestation for pre-eclampsia. Dyspnoea on exertion was noted during the pregnancy and six months after delivery she was admitted with right heart failure. CTPA excluded pulmonary embolus; but noted dilatation of pulmonary artery, moderate to severe dilatation of right atrium and moderate dilation of right ventricle with a degree of right ventricular hypertrophy. TIPSS was shown to be patent. TTE demonstrated severe PH, severely dilated right ventricle with impaired systolic function. Right heart catheterisation confirmed PH (mPAP 53 mmHg, PAWP 11 mmHg). The patient has been treated with sildenafil and intravenous Iloprost (along with warfarin) for PH and is being considered for lung transplantation assessment (patient 7; Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}).

DISCUSSION
==========

The majority of the patients affected by BCS in Western countries are women of childbearing age\[[@B1],[@B16]\], with the peak incidence in the third decade for women and in the fourth decade for men\[[@B17]\]. Fertility is generally unaffected in women with BCS as only a minority becomes cirrhotic.

Several previously reported observations suggest that pregnancy in BCS women could cause deterioration of the liver disease and pregnancy was associated with development of ascites in several women with known BCS\[[@B17]-[@B19]\]. Rautou et al\[[@B15]\] showed that the maternal outcome, in 14 women with 24 pregnancies is good in women becoming pregnant after the diagnosis and treatment of BCS. All mothers were alive at a median follow-up of 34 mo after last delivery and only one of them required liver transplantation after 73 mo follow- up.

In our series, there were no thrombotic events occurring during pregnancy or the postpartum period. This is comparable to previous study\[[@B15]\] where 2 of 17 pregnancies on anticoagulation therapy were complicated by portal vein thrombosis\[[@B15]\]. Subclavian and portal venous thrombosis has been reported in a pregnant patient with known and treated BCS secondary to (JAK 2 negative) essential thrombocytosis on anticoagulation\[[@B20]\].

Two patients had notable bleeding related to 3 deliveries in contrast to 6 patients with 7 bleeding episodes during pregnancy or postpartum in the previous study\[[@B15]\], signifying the importance of careful management of anticoagulation in pregnancy.

Both of our patients who developed pulmonary hypertension (mPAP ≥ 25 mmHg at rest) had the diagnosis of BCS and insertion of TIPSS several years ago. TIPSS has been regarded as a cardiac stress by suddenly increasing the preload leading to increased cardiac diastolic volumes and diameters, and a transient PH for 3-6 mo\[[@B21],[@B22]\]. It is usually accommodated rapidly and is then associated with a reduction in systemic vascular resistance and a reduction in afterload\[[@B22]\]. However, development of PH after one and half years following TIPSS insertion has been reported\[[@B23]\]. In a recent study looking at the long-term cardiopulmonary outcome following TIPSS in cirrhotic patients, authors found higher prevalence of PH in the TIPSS group, 1 to 5 years post TIPSS implantation\[[@B24]\]. Although the patients in that study\[[@B24]\] could could have had associated cirrhotic cardiomyopathy, conversely there appears to be a potential long-term risk of development of PH in non-cirrhotic patients with a patent, functional TIPSS. Therefore, further studies on the interactions of TIPSS and cirrhotic cardiomyopathy are warranted\[[@B25]\].

PH has also been reported as a common finding in MPN\[[@B26]\]. This possible association of PH with MPN has also been suggested by small case series and studies\[[@B27]-[@B30]\] and the exact incidence and prevalence of PH in this group of patients remain poorly defined\[[@B31]\]. MPN could possibly have had an impact on the development of PH in one of our patients (patient 6).

Current recommendations are to offer endoscopic screening for varices in patients with portal hypertension, when conception is planned and during the second trimester if not already on prophylaxis. One patient (patient 2) who had originally presented with variceal haemorrhage underwent gastroscopy in second trimester for variceal screening and was found not to have varices. Another patient (patient 5, who had right hepatic vein dilatation) had several gastroscopies for oesophageal variceal band ligation during pregnancy. None of the patients suffered variceal bleeding during pregnancy or were administered non-selective beta-blockers during pregnancy given concerns regarding use of beta-blockers in pregnancy\[[@B32],[@B33]\].

The number of deliveries by caesarean section was higher in our group of patients (7 in 10 deliveries, 70%) than in the general obstetric population in England (26%)\[[@B34]\] and the previous study (8 caesarean sections in 17 pregnancies, 47%)\[[@B15]\]. Although some of the indications for caesarean section were clearly not related to the presence of BCS (*e.g*., breech presentation, placenta praevia), the high incidence of placental disease (abruption, pre-eclampsia, fetal distress) leading to caesarean section may be related to the underlying causative aetiology of the BCS. Therefore, close maternal and fetal surveillance for placental disease should be considered in these patients.

Interestingly, for unknown reasons, incidence of ICP has been higher in our patients (4 patients in 5 pregnancies) than the normal obstetric population (0.7%-1.5%)\[[@B35],[@B36]\].

Our study supports that the maternal outcome is good in women becoming pregnant after the diagnosis and treatment of BCS. This favourable maternal outcome is likely to be attributable to improvement in management of BCS including effective decompressive treatment, management of the underlying conditions, anticoagulant therapy with careful follow-up; and management of pregnancy and delivery in multi-disciplinary settings. A possibly decreased level of significant bleeding and no thrombosis implies the benefits of very close monitoring of anticoagulation through joint clinics.

In contrast to the good overall maternal outcome seen in our set of patients, the livebirth rate of 62.5% is lower than in the general obstetric population (84%\[[@B37]\] and 85%-88%\[[@B38]\]), but is better than earlier reports and in line with the finding of Rautou et al\[[@B15]\]. Importantly, failed pregnancies occurred in only 2 out of 7 patients. One patient (patient 7) had 5 fetal losses over a 9-year period (83% of the incomplete pregnancies reported here).

Our study supports the conclusion that BCS cannot be considered a contraindication to pregnancy in stable patients. Development of PH is an important finding that needs further validation. Such patients should be managed at tertiary level care centres with multi-disciplinary involvement.

COMMENTS
========

Background
----------

Budd-Chiari syndrome (BCS) is a rare condition that results from hepatic venous outflow obstruction mainly due to the thrombosis of the hepatic veins and leading to hepatic dysfunction and portal hypertension. Patients with BCS usually have risk factors for venous thromboembolism (VTE). BCS mainly affects young women. Pregnancy is one of the risk factors for VTE and earlier studies reported that women with BCS could be at risk of developing severe exacerbation of BCS during their pregnancies.

Research frontiers
------------------

Pregnancy is an important issue in young women with known BCS. There are very few literature sources concerning the pregnancy related complications in women with known BCS. This study hotspot is to look at the outcome of pregnancies in women treated at the centre for BCS and to help other peers understand this important relationship.

Innovations and breakthroughs
-----------------------------

Several previously reported observations suggest that pregnancy in women with BCS could cause deterioration of the liver disease. In this series, maternal outcome was good. There were no thrombotic events occurring during pregnancy or the postpartum period, comparable to a large previous study. Only two patients had notable bleeding related to 3 deliveries signifying the importance of careful management of anticoagulation in pregnancy. Two out of 7 patients developed pulmonary hypertension several years after the diagnosis of BCS and insertion of TIPSS. Higher prevalence of PH up to 5 years post TIPSS in cirrhotic patients has been reported recently. There appears to be a potential long-term risk of development of PH in non-cirrhotic patients with a patent, functional TIPSS that needs further exploration. There was higher incidence of deliveries by caesarean section (7 in 10 deliveries) in this study group and was attributed to the placental disease that could be related to the underlying causative aetiology of BCS.

Applications
------------

This study supports that the maternal outcome in women becoming pregnant after the diagnosis and treatment of BCS is good. Fetal outcome beyond 20 wk gestation is also good. Close maternal and fetal surveillance for placental disease should be considered in these patients. Development of PH post TIPPS is an important finding that needs further validation. Such patients should be managed at tertiary level care centres with multi-disciplinary involvement.

Terminology
-----------

The BCS is named after a British Physician, George Budd in 1845 and a pathologist Hans Chiari who first described the features of BCS caused by the hepatic venous outflow obstruction in 1899. TIPSS-transjugular intrahepatic portosystemic shunt or transjugular intrahepatic portosystemic stent shunting is an artificial connection within the liver between the inflow portal vein and the outflow hepatic vein. This procedure is usually performed to reduce the portal pressure.

Peer-review
-----------

This is an interesting observational analysis of BCS in relation to pregnancy. Previous data are scarce and heterogeneous. The manuscript is nicely written.
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